[Federal Register Volume 61, Number 29 (Monday, February 12, 1996)]
[Notices]
[Pages 5404-5405]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-3073]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by contacting Robert Benson,
Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804
(telephone 301/496-7056 ext. 267; fax 301/402-0220). A signed
Confidential Disclosure Agreement will be required to receive copies of
the patent applications.
Attenuated Human Rotavirus Vaccine
Hoshino, Y., Kapikian, A.Z., and Chanock, R.M. (NIAID)
Filed 11 July 95 (priority to 11 Jul 94)
Serial No. 08/500,564 (CIP of 08/481,644)
Rotaviruses are recognized as the single most important etiologic
agent of severe diarrhea in both developed and nondeveloped countries.
This invention embodies an attenuated rotavirus as a vaccine. The
claims of the invention relate to the generation of a cold-adapted
virus that is not efficient in replication at normal human body
temperatures and therefore may be capable of stimulating an immune
response without causing illness. In a limited clinical trial,
administration of a cold-adapted rotavirus vaccine to 26 adults
demonstrated that the vaccine was safe, attenuated, and was capable of
inducing a virus-specific serologic response. This invention has been
PCT filed on July 11, 1995. (portfolio: Infectious Diseases--Vaccines,
viral, non-AIDS)
Method for Generating Influenza A Viruses Bearing Attenuating
Mutations in Internal Protein Genes
Murphy, B., Subbarao, K.E., Kawaoka, Y. (NIAID)
Filed 7 Jun 95
Serial No. 08/481,631 (CIP of 08/309,521, CIP of 08/123,933)
This invention describes a method of producing attenuated Influenza
A strains for use as live Influenza A virus vaccine candidates. This
method involves the introduction of three temperature-sensitive
attenuating mutations into the polymerase basic protein 2 (PB2) gene of
Influenza A virus. These mutations are introduced by site-directed
mutagenesis at specific sites into a cDNA copy of the PB2 gene. An RNA
transcript of this nutant PB2 gene is recovered into an infectious
Influenza A virus using a host range restricted helper virus. This
attending mutant PB2 gene can be transferred to each new variant of
Influenza A virus as it appears in nature. The patent application
covering this invention is available for licensing and contains claims
to: The methods of producing the attenuated strains; the attenuated
strains produced by the methods; and methods of vaccination using the
attenuated strains. Viruses containing mutant PB2 genes are also
available for licensing. (portfolio: Infectious Diseases--Vaccines,
viral, non-AIDS)
Attenuated Influenza A Virus
Palese, P., Muster, T., Murphy, B.R., Enami, M., Bergmann, M., Subbaro,
E.K., Chanock, R.M. (NIAID)
Filed 7 Jun 95 (priority to 3 Feb 92)
Serial No. 08/480,939 (FWC of 07/939,716)
This invention describes the development of a novel live attenuated
influenza A virus for use in intranasal vaccines. This virus is unique
in that it is a chimera of two influenza strains. This results in an
attenuated virus capable of invoking an immune response and therefore
protection against influenza. The claims of this invention cover a
method for generating the attenuated influenza virus, introducing the
viral construct into cell lines, and vaccinating a vertebrate with the
attenated virus. Animal studies have demonstrated that infection with
the chimeric virus leads to resistance to a challenge with wild-type
virus. (portfolio: Infectious Diseases--Vaccines, viral, non-AIDS)
Pteridine Nucleotide Analogs as Fluorescent DNA Probes
Hawkins, M.E., Pfleiderer, W., Davis, M.D., Balis, F.M. (NCI)
[[Page 5405]]
Filed 26 May 95
Serial No. 08/451,641 (DIV of 08/245,923)
The invention concerns a series of pteridine deoxyribonucleotide
analogs which are highly fluorescent and resemble purine nucleotides in
chemical structure and properties. The phosphoramidite form of these
fluorophores can be site-specifically incorporated into
oligonucleotides using conventional DNA synthesis techniques. The
fluorescence intensity of the pteridine nucleotide analogs is highly
dependent on their physicochemical environment, thus making them ideal
for the study of DNA-protein interactions. A real-time assay for HIV
integrase has been developed using one of the pteridine nucleotide
analogs that resembles guanosine. Other uses foreseen are as
fluorescent labels for DNA probes and PCR primers and for investigating
protein-DNA interactions. The claims include the phosphoramidite
derivatives of the pteridine nucleotide analogs useful as starting
materials for oligonucleotide synthesis and oligonucleotides
incorporating the pteridine nucleotide analogs. (portfolio: Gene-Based
Therapies--Research Tools and Reagents; Gene-Based Therapies--
Diagnostics)
Dated: February 1, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-3073 Filed 2-9-96; 8:45 am]
BILLING CODE 4140-01-M
